CAMP4 Therapeutics (CAMP) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed SIGA Technologies (SIGA) over the past year, gaining 16.7% versus a loss of 61.4%. SIGA Technologies is the larger company by market cap ($237.8 million vs $230.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | SIGA |
|---|---|---|
| Share price | $3.67 | $3.31 |
| Market cap | $230.30M | $237.82M |
| 1-day change | -4.43% | +1.53% |
| YTD return | -37.36% | -46.64% |
| 1-year return | +16.72% | -61.37% |
| 5-year return | — | -54.15% |
| Forward P/E | — | 3.06 |
| EPS (TTM) | $-2.32 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $8.55 |
| 52-week low | $2.86 | $2.83 |
| Distance from 52-week high | -52.65% | -61.29% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +188.01% | — |
| Average volume | 277.90K | 726.50K |
| Shares outstanding | 62.75M | 71.85M |
| Employees | 48 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed SIGA by 78.1 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
CAMP vs SIGA FAQ
Which is bigger, CAMP4 Therapeutics or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $237.82M compared with $230.30M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or SIGA?
CAMP returned +16.72% over the past 12 months, compared with -61.37% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.